Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Two-Year Assessment of Bimekizumab's Efficacy, Safety, and Treatment Retention in Chronic Plaque Psoriasis: Insights from Northern Italy's Real-World Data
To evaluate the 2-year effectiveness, safety, and drug survival of bimekizumab in routine clinical practice, and identify predictors of complete skin clearance.
Approach:
Study Design: A retrospective, multicenter, real-world observational study conducted across three dermatological referral centers in Italy.
Patient Population: Included adult patients with moderate-to-severe chronic plaque psoriasis who initiated treatment with bimekizumab between April 2023 and December 2025.
Data Collection: Clinical and demographic data were extracted from electronic medical records, including demographics, disease duration, comorbidities, and treatment details.
Key Findings:
Bimekizumab demonstrated rapid and sustained effectiveness, with 80.0% and 76.5% of patients achieving complete skin clearance (PASI100) at week 52 and 104, respectively.
Biologic-naïve patients had a 2-year drug survival rate of 91.5%, while prior biologic exposure decreased long-term treatment retention to 64.0%.
Palmo-plantar involvement, nail psoriasis, and concomitant proton pump inhibitor use were identified as independent negative predictors for achieving early complete skin clearance; however, findings derived from small subgroups should be interpreted cautiously.
Interpretation:
Findings suggest that while bimekizumab is effective over two years, prior biologic exposure negatively impacts treatment retention.
Limitations:
Findings regarding predictors of complete skin clearance derived from small subgroups should be interpreted cautiously as hypothesis-generating.
Conclusion:
Bimekizumab shows promising long-term effectiveness and safety in real-world settings for chronic plaque psoriasis.
Application of newly proposed GRAPPA and EULAR criteria in a longitudinal cohort identified progressively smaller groups of patients with early psoriatic arthritis who experienced persistently worse patient-reported outcomes.
Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
